Mitchell Kapoor
Stock Analyst at H.C. Wainwright
(4.43)
# 1,083
Out of 4,978 analysts
791
Total ratings
39.8%
Success rate
9.8%
Average return
Main Sectors:
Stocks Rated by Mitchell Kapoor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Reiterated: Buy | $344 | $247.69 | +38.88% | 4 | Sep 16, 2026 | |
| LYEL Lyell Immunopharma | Reiterated: Buy | $45 | $10.78 | +317.63% | 26 | Sep 11, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Hold | $60 | $64.73 | -7.31% | 16 | Sep 10, 2026 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Reiterated: Buy | kr 575.00 | kr 439.40 | +30.86% | 9 | Sep 10, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $45 → $30 | $24.35 | +23.20% | 38 | Sep 10, 2026 | |
| EVMN Evommune | Reiterated: Hold | n/a | $9.37 | - | 9 | Sep 9, 2026 | |
| GENB Generate Biomedicines | Reiterated: Buy | $30 | $15.68 | +91.33% | 5 | Sep 9, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $25 | $11.49 | +117.58% | 17 | Sep 9, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Sell | $5 | $19.76 | -74.70% | 35 | Sep 9, 2026 | |
| IONS Ionis Pharmaceuticals | Reiterated: Buy | $115 → $100 | $44.84 | +123.02% | 33 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 | $17.00 | +282.35% | 64 | Sep 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $115 | $108.44 | +6.05% | 61 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $93.55 | +28.27% | 19 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $29.10 | +106.19% | 2 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $17.30 | - | 38 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $25 → $15 | $7.94 | +88.92% | 25 | Sep 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $150 | $124.75 | +20.24% | 20 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $52.21 | +53.23% | 19 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $13.83 | +8.46% | 24 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $12.76 | +56.74% | 5 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $9.50 | +163.16% | 2 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.86 | +168.82% | 29 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $6.90 | +262.32% | 21 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $65 | $34.67 | +87.48% | 35 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $24.53 | +83.45% | 4 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.69 | +314.20% | 5 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $30 | $16.58 | +80.94% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $7.91 | +216.06% | 24 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.71 | +84.50% | 10 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $17.18 | - | 9 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $11 | $2.77 | +297.83% | 30 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 → $10 | $4.16 | +140.38% | 16 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $7.25 | - | 20 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $2.82 | +41.84% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.16 | +506.06% | 14 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $2 | $4.61 | n/a | 9 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $25 | $6.70 | n/a | 1 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $17.09 | n/a | 26 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0008 | n/a | 16 | Apr 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $0.756 | n/a | 24 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $5.37 | n/a | 2 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 | $2.88 | n/a | 6 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.6695 | n/a | 8 | Aug 11, 2023 |
Ascendis Pharma
Sep 16, 2026
Reiterated: Buy
Price Target: $344
Current: $247.69
Upside: +38.88%
Lyell Immunopharma
Sep 11, 2026
Reiterated: Buy
Price Target: $45
Current: $10.78
Upside: +317.63%
BioMarin Pharmaceutical
Sep 10, 2026
Reiterated: Hold
Price Target: $60
Current: $64.73
Upside: -7.31%
Swedish Orphan Biovitrum AB (publ)
Sep 10, 2026
Reiterated: Buy
Price Target: kr 575.00
Current: kr 439.40
Upside: +30.86%
Tyra Biosciences
Sep 10, 2026
Reiterated: Buy
Price Target: $45 → $30
Current: $24.35
Upside: +23.20%
Evommune
Sep 9, 2026
Reiterated: Hold
Price Target: n/a
Current: $9.37
Upside: -
Generate Biomedicines
Sep 9, 2026
Reiterated: Buy
Price Target: $30
Current: $15.68
Upside: +91.33%
Intellia Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $25
Current: $11.49
Upside: +117.58%
Sarepta Therapeutics
Sep 9, 2026
Reiterated: Sell
Price Target: $5
Current: $19.76
Upside: -74.70%
Ionis Pharmaceuticals
Sep 8, 2026
Reiterated: Buy
Price Target: $115 → $100
Current: $44.84
Upside: +123.02%
Sep 4, 2026
Reiterated: Buy
Price Target: $65
Current: $17.00
Upside: +282.35%
Sep 3, 2026
Reiterated: Buy
Price Target: $115
Current: $108.44
Upside: +6.05%
Sep 3, 2026
Reiterated: Buy
Price Target: $120
Current: $93.55
Upside: +28.27%
Sep 3, 2026
Reiterated: Buy
Price Target: $60
Current: $29.10
Upside: +106.19%
Sep 3, 2026
Reiterated: Hold
Price Target: n/a
Current: $17.30
Upside: -
Sep 2, 2026
Upgraded: Buy
Price Target: $25 → $15
Current: $7.94
Upside: +88.92%
Sep 1, 2026
Reiterated: Buy
Price Target: $150
Current: $124.75
Upside: +20.24%
Aug 31, 2026
Reiterated: Buy
Price Target: $80
Current: $52.21
Upside: +53.23%
Aug 21, 2026
Reiterated: Buy
Price Target: $15
Current: $13.83
Upside: +8.46%
Aug 14, 2026
Reiterated: Buy
Price Target: $20
Current: $12.76
Upside: +56.74%
Aug 14, 2026
Reiterated: Buy
Price Target: $25
Current: $9.50
Upside: +163.16%
Aug 13, 2026
Reiterated: Buy
Price Target: $5
Current: $1.86
Upside: +168.82%
Aug 12, 2026
Reiterated: Buy
Price Target: $25
Current: $6.90
Upside: +262.32%
Aug 12, 2026
Reiterated: Buy
Price Target: $70 → $65
Current: $34.67
Upside: +87.48%
Aug 11, 2026
Reiterated: Buy
Price Target: $45
Current: $24.53
Upside: +83.45%
Aug 11, 2026
Reiterated: Buy
Price Target: $7
Current: $1.69
Upside: +314.20%
Aug 7, 2026
Reiterated: Buy
Price Target: $35 → $30
Current: $16.58
Upside: +80.94%
Aug 7, 2026
Reiterated: Buy
Price Target: $25
Current: $7.91
Upside: +216.06%
Aug 6, 2026
Reiterated: Buy
Price Target: $5
Current: $2.71
Upside: +84.50%
Jul 31, 2026
Reiterated: Hold
Price Target: n/a
Current: $17.18
Upside: -
May 11, 2026
Reiterated: Buy
Price Target: $17 → $11
Current: $2.77
Upside: +297.83%
Jan 13, 2026
Reiterated: Buy
Price Target: $13 → $10
Current: $4.16
Upside: +140.38%
Jan 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $7.25
Upside: -
Oct 24, 2025
Reiterated: Buy
Price Target: $4
Current: $2.82
Upside: +41.84%
Oct 22, 2025
Reiterated: Buy
Price Target: $7
Current: $1.16
Upside: +506.06%
Aug 19, 2025
Reiterated: Hold
Price Target: $3 → $2
Current: $4.61
Upside: n/a
Aug 11, 2025
Initiated Coverage: Buy
Price Target: $25
Current: $6.70
Upside: n/a
Apr 30, 2025
Rated: Hold
Price Target: n/a
Current: $17.09
Upside: n/a
Apr 4, 2025
Rated: Hold
Price Target: n/a
Current: $0.0008
Upside: n/a
Apr 3, 2025
Reiterated: Buy
Price Target: $9
Current: $0.756
Upside: n/a
Mar 21, 2025
Reiterated: Buy
Price Target: $15
Current: $5.37
Upside: n/a
May 14, 2024
Reiterated: Hold
Price Target: $15
Current: $2.88
Upside: n/a
Aug 11, 2023
Reiterated: Hold
Price Target: n/a
Current: $0.6695
Upside: n/a